What is the 13F Pro Quality Score for VCYT?

13F Pro ranks VERACYTE, INC. (VCYT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VCYT's current score at https://13fpro.ai/company/VCYT (free sign-up required for the full ranking).

Which hedge funds own the most VCYT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VCYT include BlackRock,, FMR, Artisan Partners Limited Partnership. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/VCYT as soon as new 13F filings post.

Where does 13F Pro source VCYT data?

All VERACYTE, INC. fundamentals and ownership data come directly from SEC EDGAR. VERACYTE, INC. files with the SEC under CIK 1384101. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VCYT in?

VERACYTE, INC. (VCYT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives VCYT's revenue?

Per VERACYTE, INC.'s latest 10-Q filed with the SEC on 2026-07-31, the biggest revenue drivers are: Testing revenue ($145.7M, +19% YoY); Product revenue ($3.9M, +7% YoY); Biopharmaceutical and other revenue ($0.8M, -81% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/VCYT.

What are VCYT's largest expenses?

VERACYTE, INC.'s latest 10-Q reports these as the largest expense items: Cost of testing revenue ($36.3M, +12% YoY); Research and development ($29.4M, +81% YoY); Selling and marketing ($28.3M, +12% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is VCYT research updated on 13F Pro?

VCYT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

VERACYTE, INC.(VCYT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1384101 VCYT stock profile & AI dashboard →

13F Pro Quality Score

68.6/100

Rank #313 of 2,960 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

79.6/100

Profitability

84.4/100

Balance Sheet

81.1/100

Earnings Quality

75.6/100

Free Cash Flow

83.6/100

Institutional Flow

33.1/100

Revenue Scale

38.7/100

Dilution Risk

18.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why VCYT Scores 69/100

exact factor attribution · 2026-09-12

VCYT's composite is driven by revenue growth and profitability, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+5.9 pts

80th pct

Profitability

+5.2 pts

84th pct

Free cash flow

+5.0 pts

84th pct

Capital efficiency

+3.1 pts

81th pct

Earnings quality

+2.6 pts

76th pct

Earnings growth

+0.9 pts

69th pct

Institutional flow

-0.8 pts

33th pct

Shareholder dilution

-1.6 pts

18th pct

Scale

-1.7 pts

39th pct

Latest change (2026-07-31): 60 → 50 · ↓ Profit margin 78→64; ↓ Capital efficiency 63→51; despite ↑ Revenue growth 38→64

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in VCYT

Events flagged as statistical outliers against VCYT's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-07-31
VCYT quality score dropped 10 points (60→50) on a new filing
View source filing →

VCYT Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for VERACYTE, INC. (VCYT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VCYT at 68.6/100 on a 32-signal composite quality model, placing it at rank #313 of 2,960 stocks — the top 25% of the AI-ranked universe. VCYT scores in the top quartile across profitability (84.4), free cash flow (83.6), balance sheet strength (81.1). Areas of concern include institutional flow (33.1) and revenue scale (38.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), VERACYTE, INC. reports quarterly revenue of $150.3M, net income of $25.5M, an operating margin of 15.3%. Top institutional holders of VCYT by reported 13-F value include BlackRock, FMR, Artisan Partners Limited Partnership, based on the most recent SEC filings. VCYT trades on the Nasdaq exchange and files with the SEC under CIK 1384101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VCYT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VERACYTE, INC. directly from SEC EDGAR. VERACYTE, INC.'s 13F Pro composite quality score has ranged between 28 and 69 since 2021, currently 68.6 — an improving long-term trajectory across 69 quarterly and live scoring snapshots.

✦

Fun facts about VERACYTE, INC.

Quirks, history, and lore behind VCYT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. genomic diagnostics company · listed on Nasdaq · headquartered in South San Francisco, California · focused on cancer detection.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, with a business model built on test volume growth rather than near-term profitability.
3
The History
Founded in the early 2000s, the company grew by acquiring complementary diagnostics businesses and expanding beyond its original thyroid cancer testing niche.
4
The Secret
Its tests use gene expression profiling to tell surgeons whether a suspicious nodule is malignant — potentially sparing patients from unnecessary surgery.
5
The Lore
The company has pushed aggressively into urologic and breast cancers, aiming to become a one-stop genomic shop for oncologists who are tired of playing diagnostic guesswork.
6
The Giveaway
Its flagship Afirma test is the go-to molecular tool for thyroid nodule evaluation, and its ticker is just four letters away from sounding like something you'd find in a chemistry textbook.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving VCYT's Business? Latest 10-Q Breakdown

✓ 29/29 datapoints verified

AI-extracted from VERACYTE, INC.'s 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Veracyte grew Q2 FY2026 revenue 15% YoY to $150.3M on 19% testing revenue growth and swung to $23.0M operating income from a $5.3M operating loss a year earlier.

Biggest Revenue Drivers

Testing revenue$145.7M+19% YoY

Driven by a 14% volume increase, improved ASP, and prior period collections

Product revenue$3.9M+7% YoY

Primarily international sales of the Prosigna breast cancer IVD kit

Biggest Revenue Drivers

Total revenue: $150.3M+15% YoY

Testing revenue$145.7M+19% YoY

Driven by a 14% volume increase, improved ASP, and prior period collections

Product revenue$3.9M+7% YoY

Primarily international sales of the Prosigna breast cancer IVD kit

Biopharmaceutical and other revenue$0.8M-81% YoY

Discontinuation of biopharmaceutical, contract manufacturing and development services previously conducted in France following Veracyte SAS restructuring

Largest Expense Items

Cost of testing revenue$36.3M+12% YoY

Increased testing volume, higher staffing for volume and new test launches, and infrastructure buildout, partly offset by lab efficiencies

Research and development$29.4M+81% YoY

$6.5M shift of software development expenses from G&A now fully dedicated to product development, plus added headcount and merit increases

Selling and marketing$28.3M+12% YoY

Annual compensation increases, headcount additions, and tradeshow/new test launch costs

General and administrative$27.4M-15% YoY

Reassignment of software development costs to R&D and customer service costs to cost of revenue, plus lower legal, audit and tax fees

Margins: Gross profit rose 21% YoY to $108.5M as cost of revenue grew just 3% versus 15% revenue growth. Operating income reached $23.0M versus a $5.3M loss a year earlier, aided by the absence of the prior year's $20.5M non-cash impairment charge.

Watch Items from the Filing

Medicare and UnitedHealthcare together represented 46% of total revenue in Q2 2026 (33% and 13%, respectively), a significant payer concentration.
Veracyte's patent infringement suit against Sonic Healthcare USA over ThyroSeq v3 cleared a motion to dismiss, but the USPTO granted an ex parte reexamination of one asserted patent on July 21, 2026; jury trial set for Q1 next year.
R&D expense grew 81% YoY as spending shifted toward TrueMRD platform development and new IVD products, a step-up in investment ahead of any related revenue.
Cash, cash equivalents and short-term investments rose to $485.2M, up $72.3M in the first half of 2026, supported by $81.0M of operating cash flow.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$150.3M

Net Income

Q2 2026

$25.5M

Free Cash Flow

Q2 2026

$43.0M

Operating Margin

Q2 2026

15.3%

ROIC

Q2 2026

6.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+16.0% YoY

$517.1MFY 2025

FY22 $296.5MFY23 $361.1MFY24 $445.8MFY25 $517.1M

Net Income

+174.9% YoY

$66.4MFY 2025

FY22 $-36.6MFY23 $-74.4MFY24 $24.1MFY25 $66.4M

Operating Income

+257.9% YoY

$57.8MFY 2025

FY22 $-41.1MFY23 $-85.8MFY24 $16.1MFY25 $57.8M

EPS (Diluted)

+164.5% YoY

$0.82FY 2025

FY22 $-0.51FY23 $-1.02FY24 $0.31FY25 $0.82

Total Assets

+8.2% YoY

$1.41BFY 2025

FY22 $1.16BFY23 $1.11BFY24 $1.30BFY25 $1.41B

Total Debt

—FY 2025

FY22 $0.00FY23 —FY24 —FY25 —

Op. Cash Flow

+81.5% YoY

$136.3MFY 2025

FY22 $7.5MFY23 $44.2MFY24 $75.1MFY25 $136.3M

Free Cash Flow

+98.5% YoY

$126.6MFY 2025

FY22 $-1.0MFY23 $34.3MFY24 $63.8MFY25 $126.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$517.1M +16.0%	$445.8M +23.5%	$361.1M +21.8%	$296.5M +35.1%	$219.5M +86.8%	$117.5M
Net Income	$66.4M +174.9%	$24.1M +132.4%	$-74.4M -103.5%	$-36.6M +51.6%	$-75.6M -116.5%	$-34.9M
Operating Income	$57.8M +257.9%	$16.1M +118.8%	$-85.8M -108.8%	$-41.1M +49.8%	$-81.9M -131.4%	$-35.4M
EPS (Diluted)	$0.82 +164.5%	$0.31 +130.4%	$-1.02 -100.0%	$-0.51 +54.1%	$-1.11 -68.2%	$-0.66
Total Assets	$1.41B +8.2%	$1.30B +16.6%	$1.11B -3.6%	$1.16B -2.6%	$1.19B +159.8%	$457.2M
Total Debt	—	—	—	$0.00 -100.0%	$1.1M +39.1%	$810.0K
Operating Cash Flow	$136.3M +81.5%	$75.1M +69.8%	$44.2M +486.9%	$7.5M +123.8%	$-31.6M -225.6%	$-9.7M
Free Cash Flow	$126.6M +98.5%	$63.8M +86.2%	$34.3M +3478.8%	$-1.0M +97.3%	$-37.0M -194.8%	$-12.5M

Get alerted when VCYT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for VERACYTE, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VCYT

BlackRock, Inc.
$792.1M13,486,437 sh
FMR LLC
$452.4M7,702,746 sh
Artisan Partners Limited Partnership
$325.3M5,538,404 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$277.0M4,716,191 sh
STATE STREET CORP
$276.0M4,698,128 sh
VANGUARD CAPITAL MANAGEMENT LLC
$211.1M3,593,922 sh
DIMENSIONAL FUND ADVISORS LP
$166.0M2,826,524 sh
FIRST TRUST ADVISORS LP
$147.3M2,507,902 sh
ARK Investment Management LLC
$134.8M2,295,951 sh
WELLINGTON MANAGEMENT GROUP LLP
$133.6M2,274,160 sh

Fund	Value	Shares
BlackRock, Inc.	$792.1M	13,486,437
FMR LLC	$452.4M	7,702,746
Artisan Partners Limited Partnership	$325.3M	5,538,404
VANGUARD PORTFOLIO MANAGEMENT LLC	$277.0M	4,716,191
STATE STREET CORP	$276.0M	4,698,128
VANGUARD CAPITAL MANAGEMENT LLC	$211.1M	3,593,922
DIMENSIONAL FUND ADVISORS LP	$166.0M	2,826,524
FIRST TRUST ADVISORS LP	$147.3M	2,507,902
ARK Investment Management LLC	$134.8M	2,295,951
WELLINGTON MANAGEMENT GROUP LLP	$133.6M	2,274,160

Companies Similar to VCYT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VCEL

Vericel Corp

AI score

Very similar · 28 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Champlain Investment Partners, LLC Summit Creek Advisors LLC

LMAT

LEMAITRE VASCULAR INC

AI score

Similar quality profile · 12 shared holders

OBERWEIS ASSET MANAGEMENT INC/RICE HALL JAMES & ASSOCIATES, LLC SEGALL BRYANT & HAMILL, LLC

CDNA

CareDx, Inc.

AI score

Similar quality profile · 16 shared holders

ARK Investment Management LLC BAMCO INC /NY/Nikko Asset Management Americas, Inc.

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 19 shared holders

Artisan Partners Limited Partnership FRED ALGER MANAGEMENT, LLC JUPITER ASSET MANAGEMENT LTD

KRYS

Krystal Biotech, Inc.

AI score

Similar quality profile · 26 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC SEGALL BRYANT & HAMILL, LLC Granite Investment Partners, LLC

LIVN

LivaNova PLC

AI score

Similar quality profile · 17 shared holders

Artisan Partners Limited Partnership DRIEHAUS CAPITAL MANAGEMENT LLC OBERWEIS ASSET MANAGEMENT INC/

INSP

Inspire Medical Systems, Inc.

AI score

Similar quality profile · 11 shared holders

Artisan Partners Limited Partnership DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)EFG Asset Management (North America) Corp.

KNSA

Kiniksa Pharmaceuticals International, plc

AI score

Similar quality profile · 20 shared holders

DRIEHAUS CAPITAL MANAGEMENT LLC OBERWEIS ASSET MANAGEMENT INC/ArrowMark Colorado Holdings LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VCYT on your watchlist

Track score changes the day VERACYTE, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VCYT a good stock to buy?

13F Pro's AI-powered analysis of VERACYTE, INC. (VCYT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VCYT are available on the VCYT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VCYT is classified as a mid company.

Which hedge funds own VCYT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VCYT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VERACYTE, INC.'s investment landscape.